The aim of the study is 1. Statistical evaluation of patients' characteristics who have intermediate \& high risk localized prostate cancer. 2. Statistical analysis of treatment efficacy of combined hormonal therapy \& hypo fractionated intensity modulated radiotherapy compared with conventionally fractionated radiotherapy plus hormonal treatment as regard biochemical failure, disease free survival \& overall survival. 3. Evaluation of acute as well as late toxic side effects after radiotherapy.
No linked publications found in PubMed
Inclusion Criteria: * Biopsy proven prostate adenocarcinoma * Patient has been classified as intermediate or high risk according to the National Comprehensive Cancer Network v2018 . * Clinically localized stage (cT2-T3b N0M0, using the AJCC 8th TNM classification) . * Eastern Cooperative Oncology Group performance status ranged from 0-1 . - Mean age was 65 years (range: 50-80 years). * a prostate-specific antigen test at the time of diagnosis ≥10 ng/ml. * Gleason scores range from 7 to 10. * The patient must not receive any cytotoxic anticancer therapy for prostate cancer prior to randomization. * Adequate hematological, hepatic, renal function tests Exclusion Criteria: * Patients with a history of other malignancies, except: non-melanoma skin cancer. * Patients with any contraindication to pelvic radiotherapy: including, previous pelvic radiotherapy, inflammatory bowel disease or severe bladder irritability. * Patients who had prior surgical treatment for carcinoma of the prostate apart from trans-urethral resection, * Nodal or distant metastasis proven by a computed tomography pelvis or bone scan, * Co-morbidities as Congestive heart failure, recent myocardial infarction.